In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Glucometer

This article was originally published in The Gray Sheet

Executive Summary

Blood glucose self-test monitor line gains expanded FDA market clearance allowing use with blood obtained from sites other than the finger, including the forearm, palm, abdomen and thigh. The alternate site clearance includes the Bayer Glucometer Elite, Elite XL,DEX and DEX 2 systems, and makes Bayer "the only company to offer alternate site testing across its range of self-test monitors," the firm claims...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT016644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel